Lyra Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for ear, nose, and throat (ENT) diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts, USA. Lyra Therapeutics aims to address the unmet medical needs in the field of ENT by leveraging its proprietary drug delivery platform.
The company is known for LYR-210. It is a potential breakthrough treatment for chronic rhinosinusitis (CRS), a common inflammatory condition of the sinuses. LYR-210 utilizes Lyra's unique drug delivery technology, which involves the localized and sustained release of medication directly to the affected tissues in the nasal cavity. This approach has the potential to provide enhanced therapeutic efficacy while minimizing systemic side effects.
Lyra Therapeutics' drug delivery platform is based on bioresorbable polymeric nanoparticles that are administered via a minimally invasive procedure. These nanoparticles release the medication over an extended period, providing long-lasting therapeutic effects. This technology has the potential to transform the treatment landscape for ENT diseases and improve patient outcomes.
Lyra Therapeutics is a publicly traded company. It went public in July 2020 with its initial public offering (IPO) on the Nasdaq Global Market under the ticker symbol "LYRA."
Lyra Therapeutics is also actively engaged in developing other potential therapies for ENT conditions. The company's pipeline includes programs targeting conditions such as chronic rhinosinusitis with nasal polyps and acute otitis media. These programs leverage the same drug delivery platform to provide localized and sustained drug release in the affected areas.
Lyra Therapeutics collaborates with leading academic institutions, research organizations, and clinical experts to advance its scientific knowledge and drive innovation in the field of ENT. The company's team of experienced professionals, including scientists, clinicians, and business experts, are dedicated to bringing transformative therapies to patients in need.